HomeCompareBVNKF vs O

BVNKF vs O: Dividend Comparison 2026

BVNKF yields 6.73% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 O wins by $3.0K in total portfolio value· pulled ahead in Year 9
10 years
BVNKF
BVNKF
● Live price
6.73%
Share price
$29.71
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.2K
Annual income
$1,032.71
Full BVNKF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.18
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,098.20
Full O calculator →

Portfolio growth — BVNKF vs O

📍 O pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBVNKFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BVNKF + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BVNKF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BVNKF
Annual income on $10K today (after 15% tax)
$572.20/yr
After 10yr DRIP, annual income (after tax)
$877.80/yr
O
Annual income on $10K today (after 15% tax)
$448.90/yr
After 10yr DRIP, annual income (after tax)
$4,333.47/yr
At 15% tax rate, O beats the other by $3,455.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BVNKF + O for your $10,000?

BVNKF: 50%O: 50%
100% O50/50100% BVNKF
Portfolio after 10yr
$32.7K
Annual income
$3,065.46/yr
Blended yield
9.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

BVNKF
No analyst data
Altman Z
6.8
Piotroski
8/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.6% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BVNKF buys
0
O buys
0
No recent congressional trades found for BVNKF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBVNKFO
Forward yield6.73%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$31.2K$34.2K
Annual income after 10y$1,032.71$5,098.20
Total dividends collected$8.6K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: BVNKF vs O ($10,000, DRIP)

YearBVNKF PortfolioBVNKF Income/yrO PortfolioO Income/yrGap
1$11,373$673.17$10,818$607.86+$555.00BVNKF
2$12,885$715.53$11,786$741.30+$1.1KBVNKF
3$14,544$757.60$12,944$910.50+$1.6KBVNKF
4$16,362$799.23$14,343$1,127.28+$2.0KBVNKF
5$18,347$840.27$16,053$1,408.17+$2.3KBVNKF
6$20,512$880.60$18,167$1,776.65+$2.3KBVNKF
7$22,868$920.10$20,815$2,266.60+$2.1KBVNKF
8$25,428$958.68$24,179$2,927.66+$1.2KBVNKF
9← crossover$28,204$996.24$28,521$3,833.95$317.00O
10$31,211$1,032.71$34,218$5,098.20$3.0KO

BVNKF vs O: Complete Analysis 2026

BVNKFStock

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Full BVNKF Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this BVNKF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BVNKF vs SCHDBVNKF vs JEPIBVNKF vs KOBVNKF vs MAINBVNKF vs STAGBVNKF vs ADCBVNKF vs NNNBVNKF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.